Mizuho analyst Uy Ear lowered the firm’s price target on Ocugen to $3 from $5 and keeps a Buy rating on the shares post the Q4 results. Given the evolving COVID-19 vaccine market and the lack of visibility on funding for the FDA-required safety trial, the firm reduced Covaxin estimates and pushed out its launch assumption by one year.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on OCGN:
- Ocugen reports Q4 EPS (10c), consensus (10c)
- Ocugen Provides Business Update with Fourth Quarter and Full Year 2022 Financial Results
- Ocugen submits investigational NDA with FDA in phase 1 trial of OCU200
- Ocugen, Inc. Announces Submission of Investigational New Drug Application with U.S. FDA to Initiate a Phase 1 Clinical Trial Evaluating OCU200 for the Treatment of Diabetic Macular Edema
- Ocugen to Present at Retinal Vascular Disease Drug Development Summit
